
ASTS 7TH ANNUAL SURGICAL FELLOWS SYMPOSIUM LEARNING OBJECTIVES


October 4 - 6, 2013 Snowbird, Utah TESTING FOR ANTI-HLA ANTIBODIES (ALLO ANTIBODIES) USING COMMERCIALLY AVAILABLE AND APPROVED SOLID PHASE OR FLOW CYTOMETRY BASED SINGLE ANTIGEN TESTING IS CHARACTERIZED BY ALL OF THE FOLLOWING <u>EXCEPT</u>:

- 1. Determines the presence of donor specific antibody (DSA)
- 2. Determines the titre or strength of DSA
- Determines unequivocally if DSA will cause rejection
- Does not measure T cell reactivity to alloantigen
- Provides a qualitative but not precise quantitative, reproducible measure of alloantibody and DSA






- 1. A Branch of Federal Intelligence Org
- 2. Systems Improvement Agreement
- 3. Mandated by UNOS
- Necessary to start a transplant program




WHICH OF THE FOLLOWING IS FALSE?

- 1. Heparocellular carcinoma (HCC) accounts for 40% of the liver transplants performed in the US.
- 2. More than 80% of HCC arises in cirrhotic patients with a 1% to 6% annual incidence
- 3. Patients with T2 HCC have a significantly higher incidence of wait list "drop out" and lower incidence of transplant at 90-days as compared to patients without HCC
- **4**. 1 & 3
- 5. All of the above



AFTER 5 YEARS OF DELIBERATIONS, UNOS HAS APPROVED A NEW KIDNEY ALLOCATION SYSTEM THAT WILL BE INITIATED WITHIN THE NEXT 2 YEARS. WHICH OF THE FOLLOWING IS TRUE REGARDING THE NEW ALLOCATIONS SYSTEM?

- Unlike the current allocation system, the new allocation system will initiate waiting time at the time of evaluation and listing
- 2. Unlike the current allocation system, recipients with a calculated PRA of 30% will be able to receive compatible kidneys from the national pool
- In the new allocation system, a deceased donor over the age of 60 will be classified as an extended criteria donor
- Unlike the current allocation system, the donor risk index will be used in the allocation algorithm



69%